Stephens analyst Sudan Loganathan raised the firm’s price target on Arvinas (ARVN) to $15 from $14 and keeps an Overweight rating on the shares. Q3 results were broadly in-line, notes the analyst, who sees forward value in ARV-393, ARV-102, and ARV-806 given “encouraging” early data across these assets and now incorporates ARV-102 into the firm’s valuation framework.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Holding Company: Balancing Potential and Uncertainty with a Hold Rating
- Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding Company
- Arvinas Reports Q3 2025 Earnings and Strategic Progress
- Arvinas Earnings Call: Promising Pipeline Amid Revenue Challenges
- Cautious Hold Rating for Arvinas Holding: Balancing Promising Pipeline with Clinical Uncertainties